Skip to main content

Relapsed/Refractory Follicular Lymphoma

Help Us Make Your NHL Journey as Smooth & Pain-free As Possible

Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), representing 20% to 30% of all of the other types. Relapse of FL within 24 months of chemoimmunotherapy is seen quite commonly in patients. We strive to bring a therapy to treat patients with relapsed lymphoma. 

Revive Research Institute is taking this challenge utilizing new medical technologies and improved treatment modalities to treat relapsed cases of lymphoma. Our research will bring hope to many lives play a role in making the road ahead of you as comfortable and easy as possible.

Participation criteria:

  • Males or females are ≥18 years of age.
  • Histologically confirmed follicular lymphoma.
  • Comply with study procedures.
  • Additional criteria may apply.

Revive Research Institute is part of your journey with NHL. Our group of LICENSED and certified physicians will keep track of your progress throughout the study and address any concerns or queries you may have about the research trial.

Please provide YOUR contact information only.

If you require any further information, feel free to contact us at 248-564-1485.

Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI
48034

T: 248-564-1485
E: info@rev-research.com